Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.50 |
| ▸ | TYR | P14679 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | CTSG | P08311 | 1/20 | 0.38 |
| ▸ | HMGCR | P04035 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | IAPP | P10997 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5588615 | 0.89 | PRKCI (0.52) | PRKCITYRCNR1CNR2ALOX5 | |
| SCHEMBL5677727 | 0.88 | TYR (0.52) | PRKCITYRALOX5ELANECTSG | |
| Hydrochloric Acid SCHEMBL21409697 | 0.88 | PRKCI (0.50) | PRKCITYRCNR1CNR2ALOX5 | |
| SCHEMBL5676388 | 0.86 | TYR (0.59) | TYRALOX5ELANECTSG | |
| SCHEMBL26046465 | 0.86 | PRKCI (0.49) | PRKCITYRCNR1CNR2ALOX5 | |
| SCHEMBL9325680 | 0.85 | GABRA1 (0.48) | PRKCITYRELANECTSGHMGCR | |
| SCHEMBL31152502 | 0.85 | PRKCI (0.47) | PRKCITYRCNR1CNR2ALOX5 | |
| SCHEMBL31152499 | 0.85 | PRKCI (0.47) | PRKCITYRCNR1CNR2ALOX5 | |
| SCHEMBL5589782 | 0.85 | GABRA1 (0.46) | PRKCITYRGABRA1GABRB2IAPP | |
| SCHEMBL5676407 | 0.84 | TYR (0.51) | PRKCITYRALOX5ELANECTSG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060036049-A1 | Soluble late transition metal catalysts for olefin oligomerizations III | ZHAO BAIYI | 2006-02-16 | — | — | US | disclosed |
| EP-1620447-A1 | SOLUBLE LATE TRANSITION METAL CATALYSTS FOR OLEFIN OLIGOMERIZATIONS III | Exxonmobil Chemical Patents Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| WO-2003102006-A1 | SOLUBLE LATE TRANSITION METAL CATALYSTS FOR OLEFIN OLIGOMERIZATIONS III | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060036049-A1 | Soluble late transition metal catalysts for olefin oligomerizations III | COMT, CD69, SPR | PRKCI 4096/4885TYR 275/4885CNR1 3890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.